Cencora, Inc.

Cencora, Inc. is a US-based company specializing in facilitating drug development and commercialization for biopharmaceutical firms, offering services in logistics, clinical support, and patient access solutions. Founded in 2001 by Steven Graham, Cencora, Inc. provides comprehensive support for biopharmaceutical development.

Headquartered in the US, the company has successfully completed 7 deals and raised a total of USD 694. 00 mn in funding, with the latest round being an Exit in 2011. Steven Graham has a background in founding other ventures, showcasing his extensive experience in the industry. Cencora specializes in a comprehensive suite of offerings designed to streamline the drug development and commercialization process for biopharmaceutical companies.

Their core products and services include logistics and warehousing, drug research and clinical development support, commercialization assistance, and patient access solutions. These services enhance the speed-to-market of therapeutic products while addressing barriers to patient access, ultimately improving health outcomes. The company serves a diverse client base, including pharmaceutical manufacturers, healthcare providers, and pharmacies, focusing on North America, Europe, and select markets in Asia and Latin America. By leveraging a global network, Cencora ensures safe storage and timely delivery of medications, facilitating efficient healthcare delivery across these regions.

In the most recent fiscal year, Cencora reported a revenue of USD 78,695. 66 mn and an EBITDA of USD 1,290. 88 mn. The company generates revenue primarily through B2B partnerships with pharmaceutical manufacturers and healthcare providers, focusing on service fees related to logistics, regulatory compliance, and commercialization support services.

Their tailored pricing plans cater to the specific needs of clients, with flagship offerings, such as innovative pharmacy solutions and integrated biopharma support, contributing to revenue generation. Cencora plans to expand its product offerings and geographic presence in the coming years. The company is exploring new markets in Asia and Latin America, aiming for entry by 2025. Recent funding, amounting to USD 694.

00 mn from the Exit round, will be utilized to bolster development efforts for new services and enhance operational capabilities across these targeted regions, ensuring better access to their solutions in emerging markets.